ArticleClinical rheumatology2026
Foot and ankle arthritis in rheumatoid arthritis: prevalence and clinical correlation with disease activity.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionsFoot and ankle arthritis (FAA) in Rheumatoid Arthritis (RA) patients is an under-recognized clinical problem. Patients may have FAA in a disease remission state as most of the disease severity calculation consider 28 joints excluding FAA. Our objective was to estimate the prevalence of FAA, and to determine its correlation with disease activity and other clinical variables.
methodsA cross-sectional study was conducted from 2022 to 2023 among 201 RA patients, meeting 2010 ACR/EULAR criteria. Clinical assessment, joint examination (including foot and ankle), laboratory parameters, and disease activity scores (CDAI, DAS28, SDAI) were recorded.
resultsAmong the 201 RA participants, 65.0% were female, 75.1% had advanced disease, and 25.4% had comorbidity. The mean age was 44.7 ± 11.48 years. FAA was reported in 46.8% of patients, with more frequent ankle involvement (30.3%) than MTP joints (14.4%). However, 35.3% had FAA in the past. FAA was significantly associated with higher ESR (p < 0.01), pain scores (VAS) [ p = 0.001], conventional disease modifying drugs (csDMARDs) [p = 0.009] and higher swollen joint count/tender joint count (p < 0.05). FAA correlated significantly with higher disease activity scores (CDAI, SDAI, DAS28; p < 0.001). No significant association was found with age, comorbidities, BMI, disease duration, serology, or steroid use.
conclusionThe prevalence of FAA is high in RA and strongly associated with increased disease activity despite being excluded from standard indices. These findings highlight the need to incorporate foot and ankle assessments into routine RA evaluations. Key Points •FAA is commonly affected in RA and may be considered when assessing disease activity. •FAA showed a significant association with higher disease activity, even though it is excluded from disease activity score.
Indexed as
Identifiers
41547685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.